Transfusion is generally very safe. However, in a small number of cases, it leads to mild and even serious - life-threatening - hazards (most often after platelet component transfusion). In cases where no preventable accident happens (that exclude infection, chain error, malpractice, antigen-antibody conflict), the symptomatology resembles inflammation. The present essay reports on the causes of inflammation in transfusion and in which way one may intervene on the different steps of the process -from donor to patient - to limit such incidents/accidents.
EpsteinJS. Best practices in regulation of blood and blood products. Biologicals2012; 40:200–204.
2.
Council of Europe (EDQM). Guide to the preparation, use and quality assurance of blood components. 17th Edition. Strasbourg, France, 2013.
3.
HeddleNMKlamaLSingerJRichardsCFedakPWalkerIKeltonJG. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med1994; 331:625–28.
4.
LannanKLSahlerJSpinelliSLPhippsRPBlumbergN. Transfusion immunomodulation—the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis2013; 50:61–68.
5.
GarraudOHamzeh-CognasseHPozzettoBCavaillonJMCognasseF. Bench to Bedside Review: Platelets and active immune functions—New clues for immunopathology?Crit Care2013; 17:236.
6.
CognasseFHamzeh-CognasseHLafargeS. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: An in vitro study. Transfusion2009; 49:91–98.
7.
NguyenKAChavarinPArthaudCACognasseFGarraudO. Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently?Blood Transfus2013; 11:152–53.
8.
PhippsRPKaufmanJBlumbergN. Platelet derived CD 154 (CD40 ligand) and febrile responses to transfusion. Lancet2001; 357:2023–24.
9.
DaneseSFiocchiC. Platelet activation and the CD40/CD40 ligand pathway: Mechanisms and implications for human disease. Crit Rev Immunol2005; 25:103–21.
10.
LangerHFChavakisT. Platelets and neurovascular inflammation. Thromb Haemost2013; 110:888–93.
11.
SiddiquiTIKumarKS AnilDikshitDK. Platelets and atherothrombosis: Causes, targets and treatments for thrombosis. Curr Med Chem2013; 20:2779–97.
12.
BlumbergNGettingsKFTurnerCHealJMPhippsRP. An association of soluble CD40 ligand (CD 154) with adverse reactions to platelet transfusions. Transfusion2006; 46:1813–21.
13.
CognasseFPayratJMCorashLOsselaerJCGarraudO. Platelet components associated with acute transfusion reactions: The role of platelet-derived soluble CD40 ligand, Blood2008; 112:4779–80.
Hamzeh-CognasseHDamienPNguyenKA. Immune reactive soluble OX40-ligand, soluble CD40-ligand, and interleukin-27 are simultaneously over secreted in platelet components associated with acute transfusion reactions. Transfusion2013; doi: 10.1111/trf. 12378.
16.
NguyenKAHamzh-CognasseHSebbanM. A computerized model of hazardous inflammatory platelet transfusion outcome. PlosOne2014 (in press).
17.
LacroixRDignat-GeorgeF. Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation. Thromb Res2012; 129(S)2:S27–S29.
18.
SaasPAngelotFBardiauxLSeiliesEGarnache-OttouFPerrucheS. Phosphatidylserine-expressing cell by-products in transfusion: A pro-inflammatory or an anti-inflammatory effect?Transfus Clin Biol2012; 19:90–97.
19.
WestFBSillimanCC. Transfusion-related acute lung injury: Advances in understanding the role of proinflammatory mediators in its genesis. Expert Rev Hematol2013; 6:265–76.
20.
CognasseFHamzehHChavarinPAcquartSGeninCGarraudO. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol2005; 83:196–98.
21.
SavageWJTobianAARSavageJHWoodRASchroederJTNessPM. Scratching the surface of allergic transfusion reactions. Transfusion2013; 53:1361–71.
22.
BerthetJDamienPHamzeh-CognasseHPozzettoBGarraudOCognasseF. Toll-like receptor 4 signal transduction in platelets: Novel pathways. Br J Haematol2010; 151:89–92.
23.
SilvainJAbtanJKerneisM. Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients the transfusion-2 study. J Am Coll Cardiol2013 doi: 10.1016/j.jacc.2013.11.029.
24.
RubinOCanelliniGDelobelJLionNTissotJD. Red blood cell microparticles: Clinical relevance. Transfus Med Hemother2012; 39:342–47.
25.
RadwanskiKGarraudOCognasseFHamzeh-CognasseHPayratJMMinK. The effects of red blood cell preparation method on in vitro markers of red blood cell aging and inflammatory response. Transfusion2013; doi: 10.1111/trf.12143.
